Novo Nordisk stock falls 2.53 percent after strategy update

Novo Nordisk stock fell 2.53 percent to DKK 252.25 on Nasdaq Copenhagen on September 23, 2026. The move followed a strategy update that put more than five potential multi-blockbuster launches by 2030 and more than DKK 150 billion in risk-adjusted pipeline sales by 2035 at the center of the investment debate.

Five launches by 2030

According to Globenewswire in the September 21, 2026, Capital Markets Day release, Novo aims to launch more than five multi-blockbusters by 2030 and deliver more than DKK 150 billion in pipeline sales in 2035. The company also targets more than 60 million patients globally by 2030.

The same strategy sets a capacity goal to serve 10 times more people with obesity through oral GLP-1 treatments. Novo also expects 2026 to 2030 revenue growth to track industry peers while maintaining a broadly stable operating margin, but the release states that these ambitions are not formal financial guidance.

H1 sales rose 18 percent

Novo's latest reported operating picture remains numerically large. In H1 2026, net sales reached DKK 175.3 billion, up 18 percent from DKK 154.9 billion in H1 2025, while net income stood at DKK 69.5 billion compared with DKK 55.5 billion a year earlier, according to Beancount.

The comparison explains the tension in the stock. H1 sales still expanded by 18 percent, yet the strategic plan only commits to revenue growth in line with peers through 2030. For investors, the key issue is the distance between strong current scale and the more measured long-term growth ambition.

Stock stays below September levels

Novo Nordisk stock stood at DKK 252.25 on Nasdaq Copenhagen on September 23, 2026, with a daily change of minus 2.53 percent. The shares were down 7.47 percent over five trading days and 22.44 percent since January 1, 2026.